CGM Accuracy & Validation Patent Landscape 2026
Continuous glucose monitor accuracy and validation IP is highly concentrated, with Medtronic MiniMed commanding the largest share among the top filers and the top five applicants together accounting for nearly two-thirds of the leading hundred filers’ combined output. The field peaked in 2021 and annual volume has since eased, though AI-based calibration and digital-health integration remain active adjacent branches attracting new entrants.
Medtronic MiniMed leads a highly concentrated field
Medtronic MiniMed holds the top position in CGM accuracy and validation IP, recording 144 patent records — more than any other applicant in the ranking. Ascensia Diabetes Care follows at 84, and Dexcom sits third at 38, creating a pronounced three-tier structure at the top.
The top five applicants together account for 64% of the hundred largest filers’ combined patent records, signalling a field where a small number of incumbents exercise strong positional control. The gap between the first-ranked applicant and the rest of the field is especially wide: Medtronic MiniMed’s count is nearly 70% larger than Ascensia’s.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic MiniMed Inc | 144 | |
| 2 | Ascensia Diabetes Care Holdings AG | 84 | |
| 3 | Dexcom Inc | 38 | |
| 4 | I-SENS Inc | 18 | |
| 5 | University of Virginia Patent Foundation | 15 | |
| 6 | Allez Health Inc | 13 | |
| 7 | Willow Laboratories Inc | 12 | |
| 8 | Abbott Diabetes Care Inc | 10 | |
| 9 | UXN Ltd | 8 | |
| 10 | SOGANG UNIV RES & BUSINESS DEV FOUND | 6 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Tingo Medical Ltd | 6 | |
| 12 | University of Padova | 6 | |
| 13 | Cercacor Laboratories Inc | 4 | |
| 14 | Cambridge Enterprise Ltd | 4 | |
| 15 | Children’s Medical Center Corporation | 3 | |
| 16 | Glutalor Medical Inc | 3 | |
| 17 | Massachusetts Institute of Technology | 3 | |
| 18 | Suzhou Zhongxing Medical Technology Co Ltd | 3 | |
| 19 | Sanvita Medical Corp | 3 | |
| 20 | Roche Diabetes Care GmbH | 3 |
This degree of concentration implies that new entrants and challengers will face substantial prior-art density in core sensor-accuracy and calibration methods, and that incremental differentiation in adjacent branches — such as AI-driven calibration or healthcare informatics — may offer more accessible entry points.
The most recent 18–24 months of filing data are subject to publication lag and will undercount actual activity; conclusions about very recent trends should be treated as provisional. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2021 peak, a dominant diagnostic branch, and emerging digital layers
Two charts capture the field’s trajectory: an annual filing trend that reveals the rise and post-peak easing of activity, and a technology-composition breakdown that shows where inventors have concentrated their claims and where adjacent branches remain comparatively thin.
Annual filing trend
Filings climbed from 17 records in 2017 to a peak of 73 in 2021, then eased to 23 in 2022 and have trended lower since. Data for 2024–2026 is subject to publication lag and materially undercounts actual filings; the apparent decline in those years should not be read as a structural retreat.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis & surgery) is the dominant branch by a large margin, reflecting the field’s core focus on in-vivo glucose sensing. G01N (Material analysis & testing) and G16H (Healthcare informatics) form a secondary tier, while branches such as G06N (AI models), H04M (Telephonic communication), and C12Q (Enzyme/DNA-based measurement) each carry notably fewer records, marking them as comparatively under-served relative to the core.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Retrospective retrofitting method to generate a co…
Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycaemic-regulation therapies. To define those outcome metrics… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Glucose sensors and methods of manufacturing | 293 |
| 2 | Electrochemical glucose sensing by equilibrium glu… | 151 |
| 3 | Method, system and computer program product for re… | 108 |
| 4 | Methods, systems, and devices for calibration and … | 61 |
| 5 | Use of electrochemical impedance spectroscopy (EIS… | 44 |
| 6 | Methods for continuous glucose monitoring | 40 |
| 7 | Systems and methods for continuous health monitori… | 39 |
| 8 | Sensing Fluid Concentration for Continuous Glucose… | 39 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the IP structure means for R&D investment decisions
The combination of high concentration, a post-peak filing trend, and thin coverage in AI and digital-health branches shapes the risk-reward calculus for any organisation considering entry or expansion in CGM accuracy and validation.
Post-peak field with incumbents still active
The lifecycle evidence classifies this field as Decline, with annual filings easing back from the 2021 peak. Core sensor-accuracy and electrochemical-calibration claims are densely covered by incumbent IP. New work is more likely to find room in software-defined validation, AI calibration, and data-transmission layers than in the saturated electrochemical sensing core.
Lifecycle: DeclineTop five control nearly two-thirds of leading-filer output
The top five applicants — Medtronic MiniMed, Ascensia Diabetes Care, Dexcom, I-SENS, and University of Virginia Patent Foundation — account for 64% of the hundred largest filers’ combined patent records. This depth of concentration means that freedom-to-operate analysis is unavoidable before entering core accuracy and calibration claim space. Challengers should map the white space in adjacent IPC branches before committing R&D resources.
High concentrationUniversity–industry partnerships anchor applied research
The most active co-filing pair is I-SENS / Allez Health with Sogang University Research & Business Development Foundation at 6 joint records, followed by Abbott Diabetes Care and Cambridge Enterprise at 4 records. The University of Virginia Patent Foundation co-files with both Abbott Diabetes Care (3 records) and Novo Nordisk (1 record). University of Padova co-files with Mayo Foundation for Medical Education & Research at 2 records. These partnerships signal that sensor-chemistry and algorithmic-validation advances are still emerging from academic collaboration rather than solely from internal corporate R&D.
Academic co-filing activeUS-centric filing with selective European and APAC coverage
The United States is the primary jurisdiction with 157 patent records, followed by Europe (EPO) at 64 and WIPO PCT at 36. Canada, China, Japan, and Australia each carry meaningful record counts. Notably, South Korea appears with only 2 records despite the presence of South Korean applicants I-SENS and Sogang University in the ranking, suggesting that some domestic filers prioritise US and EPO coverage over home-market protection. Emerging markets such as India (12 records) are present but thin.
US-led geographyGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| I-SENS Inc | SOGANG UNIV RES & BUSINESS DEV FOUND | 6 |
| Abbott Diabetes Care Inc | Cambridge Enterprise Ltd | 4 |
| University of Virginia Patent Foundation | Abbott Diabetes Care Inc | 3 |
| University of Padova | Mayo Foundation for Medical Education & Research | 2 |
| University of Virginia Patent Foundation | Novo Nordisk A/S | 1 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Medtronic MiniMed leads; Dexcom and Allez Health are new entrants gaining ground
The competitive picture divides into a dominant incumbent cluster and a group of new entrants whose recent filing momentum contrasts with the overall post-peak trend. Technology emphasis further differentiates players: some concentrate on core diagnostic sensing, others are building into informatics and digital data processing.
Medtronic MiniMed Inc
Medtronic MiniMed holds 144 patent records — the largest count in the ranking and nearly double the second-ranked applicant. Its technology emphasis centres on A61B 5 (in-vivo diagnosis, 143 records), with meaningful positions in A61M 5 (fluid delivery, 43 records) and G01N 27 (electrochemical material analysis, 42 records), reflecting full-stack coverage from sensor design through delivery integration. Recent momentum shows a moderate decline of 15% versus its prior three-year window, consistent with the field’s post-2021 easing but not signalling a withdrawal.
patent records: 144Dexcom Inc
Dexcom holds 38 patent records and, unlike most incumbents, enters the recent period as a new entrant by momentum trend — meaning it had negligible prior-period filings and is building its accuracy and validation portfolio from a low base. Its technology mix leans toward A61B 5 (29 records) but adds a meaningful stake in G16H 10 (healthcare informatics, 11 records) and G06F 21 (digital data processing, 9 records), indicating a strategy that combines sensor accuracy with data-security and informatics claims — a differentiated profile relative to Medtronic MiniMed’s hardware-heavy emphasis.
patent records: 38| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Medtronic MiniMed Inc | 28 | ▼ -15% |
| Ascensia Diabetes Care Holdings AG | 6 | ▼ -92% |
| Dexcom Inc | 7 | ▲ new entrant |
| University of Virginia Patent Foundation | 1 | ▲ new entrant |
| Allez Health Inc | 11 | ▲ new entrant |
Under-served branches in AI calibration and digital data processing
Several IPC branches appear at materially lower record counts than the dominant A61B core, suggesting they are comparatively under-served relative to the technical value they could deliver in CGM accuracy and validation workflows. These are observations of relative sparsity; technical and regulatory feasibility should be independently assessed before treating any branch as an investment target.
G06N · AI and machine-learning calibration models
G06N (Computing based on AI models) carries only 17 patent records — 2% of the branch tally — despite the well-established role of machine-learning algorithms in compensating for sensor drift, temperature artefacts, and inter-patient variability in CGM systems. The entry path is realistic: AI calibration methods can be claimed independently of hardware, reducing manufacturing barriers, and Dexcom’s informatics-oriented filing trajectory signals that at least one major player is moving in this direction. Organisations with signal-processing or predictive-modelling competencies could find defensible claim space here.
Search this in Eureka →G06F · Digital data processing and secure data pipelines
G06F (Electric digital data processing) holds 23 patent records — 3% of the branch tally — covering areas such as data integrity, secure transmission, and algorithmic processing of CGM readings. As regulatory scrutiny of software-as-a-medical-device (SaMD) and cybersecurity for connected glucose monitors intensifies, claims in this space carry increasing commercial relevance. Dexcom’s existing G06F 21 filings indicate early positioning, but the branch remains sparsely populated relative to its regulatory and commercial importance, and players with software security or health-data-platform expertise could enter without directly confronting dense sensor-chemistry prior art.
Search this in Eureka →How leaders differ across technology routes
Route coverage across the main technology branches in the current evidence set.
| Player | A61B 5 · Diagnosis & surgery | A61M 5 · Devices for body fluids | G01N 27 · Material analysis & testing | G01N 33 · Material analysis & testing | G16H 40 · Healthcare informatics |
|---|---|---|---|---|---|
| Medtronic MiniMed Inc | Strong · 143 | Moderate · 43 | Moderate · 42 | Emerging · 11 | Emerging · 18 |
| Ascensia Diabetes Care Holdings AG | Strong · 84 | Emerging · 2 | Emerging · 3 | Emerging · 14 | Emerging · 8 |
| Dexcom Inc | Strong · 29 | Absent | Absent | Absent | Moderate · 9 |
| University of Virginia Patent Foundation | Strong · 10 | Strong · 8 | Absent | Strong · 8 | Strong · 6 |
| I-SENS Inc | Strong · 18 | Absent | Emerging · 1 | Absent | Absent |
| Abbott Diabetes Care Inc | Strong · 10 | Moderate · 4 | Absent | Absent | Absent |
| Allez Health Inc | Strong · 13 | Absent | Absent | Absent | Absent |
Frequently asked questions
Medtronic MiniMed Inc leads with 144 patent records, followed by Ascensia Diabetes Care Holdings AG at 84 and Dexcom Inc at 38. These three applicants together account for the bulk of the top-tier concentration in this field.
The field peaked in 2021 at 73 annual records and has since eased back, consistent with a post-peak lifecycle stage. Data for 2024 and 2025 are subject to publication lag and materially undercount actual recent activity, so the apparent low figures in those years should not be read as a confirmed structural decline.
The United States is the primary jurisdiction with 157 patent records. Europe (EPO) follows at 64, with WIPO PCT at 36, Canada at 35, China at 31, Japan at 26, and Australia at 23. Coverage in South Korea and India is present but comparatively thin.
Yes. The most active co-filing pair is I-SENS / Allez Health with Sogang University Research & Business Development Foundation at 6 joint records. Abbott Diabetes Care and Cambridge Enterprise have co-filed 4 records, and the University of Virginia Patent Foundation co-files with both Abbott Diabetes Care and Novo Nordisk. University of Padova and Mayo Foundation for Medical Education & Research have 2 joint records.
The most-cited work in the corpus covers glucose sensor manufacturing (293 citations), electrochemical glucose sensing by equilibrium methods (151 citations), and computational methods for real-time glucose monitoring (108 citations). Calibration methods and electrochemical impedance spectroscopy applications also feature prominently in the top-cited list.
G06N (AI models, 17 records) and G06F (digital data processing, 23 records) are materially thinner than the dominant A61B branch. C12Q (enzyme/DNA-based measurement, 7 records), H04M (telephonic communication, 11 records), and A61P (therapeutic activity, 11 records) are also comparatively sparse. These observations of relative sparsity do not by themselves confirm commercial opportunity; technical and regulatory feasibility should be assessed independently.
Ready to map your own CGM accuracy and validation landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.